A triple combination therapy identified using newly developed cell models is showing promise for treating sporadic ALS, per a study.

Meaningful efficacy observed in slow-progressor subgroup; NfL biomarker improvements support potential for accelerated regulatory pathway SEOUL, South Korea, May 29, 2025 /PRNewswire/ -- Neuronata-R®, ...

A phase II clinical trial in people with amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, suggests that transplanting human stem cells into the spinal cord may be done safely. The ...

Amyotrophic lateral sclerosis (ALS) is an incurable neurological disorder affecting motor neurons (MNs), which are nerve cells in the brain and spinal cord that control voluntary muscle movement and ...

CLEVELAND—Amyotrophic lateral sclerosis (ALS), known as Lou Gehrig’s disease, is an incurable neurological disorder affecting motor neurons—nerve cells in the brain and spinal cord that control ...

BREMERTON, WA / ACCESS Newswire / July 7, 2025 / On July 4, 1939, Lou Gehrig delivered his iconic “luckiest man” speech, announcing his retirement from the New York Yankees. On that day, ALS ended his ...

The Independent Citizens Oversight Committee of the California Institute for Regenerative Medicine approved yesterday a $6.3 million grant to a research team from the University of California, San ...

Just as they served our country for years – fighting to protect all of us – these naval aviators are still fighting today … fighting to change regulatory law … fighting to protect the 32,000 people ...